• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝外疾病不应排除转移性神经内分泌癌的经动脉化疗栓塞治疗。

Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma.

机构信息

Department of Surgery, Riverside Methodist Hospital, Columbus, OH, USA.

出版信息

Ann Surg Oncol. 2013 Apr;20(4):1114-20. doi: 10.1245/s10434-012-2786-4. Epub 2013 Mar 2.

DOI:10.1245/s10434-012-2786-4
PMID:23456380
Abstract

BACKGROUND

Transarterial chemoembolization (TACE) is often utilized for patients with inoperable neuroendocrine carcinoma liver metastases. Often, metastatic disease is not limited to the liver. The impact of extrahepatic disease (EHD) on outcomes and response after TACE has not been described.

METHODS

We reviewed 192 patients who underwent TACE for large hepatic tumor burden, progression of liver metastases, or poorly controlled carcinoid syndrome due to neuroendocrine carcinoma. Demographics, clinicopathologic characteristics, response to TACE, complications, and survival were compared between patients with (n = 123) and without (n = 69) EHD.

RESULTS

Demographics, histopathologic characteristics, and complications were similar between groups. As well, those with and without EHD had similar biochemical (85 vs. 88 %) and radiographic response (76 vs. 79 %) to TACE (all p = NS); however, symptomatic responses were improved in those with EHD (79 vs. 60 %, p = 0.01). The group without EHD had better overall survival compared to those with EHD disease at the time of TACE (median 62 vs. 28 months, p = 0.001).

DISCUSSION

Although patients with EHD from neuroendocrine carcinoma experience shorter overall survival after TACE compared to those without EHD, they had similar symptomatic, biochemical, and radiographic response to TACE. Meaningful response to TACE is still possible in the presence of EHD and should be considered, particularly in those with carcinoid syndrome.

摘要

背景

经动脉化疗栓塞术(TACE)常用于治疗无法手术的神经内分泌癌肝转移患者。通常,转移性疾病并不局限于肝脏。肝外疾病(EHD)对 TACE 后结局和反应的影响尚未描述。

方法

我们回顾了 192 例因大肝肿瘤负荷、肝转移进展或神经内分泌癌引起的类癌综合征无法控制而行 TACE 的患者。比较了有(n=123)和无(n=69)EHD 患者的人口统计学、临床病理特征、TACE 反应、并发症和生存情况。

结果

两组患者的人口统计学、组织病理学特征和并发症相似。同样,有和无 EHD 的患者 TACE 的生化反应(85%与 88%)和影像学反应(76%与 79%)相似(所有 p 值均>0.05);然而,有 EHD 的患者症状反应更好(79%与 60%,p=0.01)。在 TACE 时患有 EHD 的患者总体生存率明显低于无 EHD 的患者(中位生存时间 62 个月与 28 个月,p=0.001)。

讨论

尽管与无 EHD 的患者相比,患有 EHD 的神经内分泌癌患者在接受 TACE 后总体生存率较短,但他们对 TACE 的症状、生化和影像学反应相似。在存在 EHD 的情况下,TACE 仍有可能获得有意义的反应,特别是在患有类癌综合征的患者中应考虑进行 TACE。

相似文献

1
Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma.肝外疾病不应排除转移性神经内分泌癌的经动脉化疗栓塞治疗。
Ann Surg Oncol. 2013 Apr;20(4):1114-20. doi: 10.1245/s10434-012-2786-4. Epub 2013 Mar 2.
2
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.肝动脉栓塞和化疗栓塞治疗转移性神经内分泌肿瘤患者:影响缓解率和生存率的变量
Cancer. 2005 Oct 15;104(8):1590-602. doi: 10.1002/cncr.21389.
3
Transarterial chemoembolization is ineffective for neuroendocrine tumors metastatic to the caudate lobe: a single institution review.经动脉化疗栓塞术对转移至尾状叶的神经内分泌肿瘤无效:单机构回顾分析
World J Surg Oncol. 2015 May 1;13:167. doi: 10.1186/s12957-015-0551-4.
4
Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.炎症标志物与不可切除肝细胞癌患者经肝动脉化疗栓塞治疗后的预后相关。
Ann Surg Oncol. 2013 Mar;20(3):923-8. doi: 10.1245/s10434-012-2639-1. Epub 2012 Sep 11.
5
Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients.经动脉化疗栓塞术治疗Child-Pugh A级和B级不可切除早期肝细胞癌:96例中国患者的对比研究结果
Am J Gastroenterol. 2003 May;98(5):1181-5. doi: 10.1111/j.1572-0241.2003.07404.x.
6
The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization.老年肝细胞癌患者经肝动脉化疗栓塞治疗的结果。
Cancer. 2009 Dec 1;115(23):5507-15. doi: 10.1002/cncr.24636.
7
Impact of neoadjuvant transarterial chemoembolization on tumor recurrence and patient survival after liver transplantation for hepatocellular carcinoma: a retrospective analysis.新辅助经肝动脉化疗栓塞对肝癌肝移植术后肿瘤复发和患者生存的影响:一项回顾性分析。
Clin Transplant. 2012 Sep-Oct;26(5):764-74. doi: 10.1111/j.1399-0012.2012.01609.x. Epub 2012 Mar 20.
8
Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver.神经内分泌肿瘤肝转移的化疗栓塞和单纯栓塞
J Vasc Interv Radiol. 2007 Jul;18(7):847-55. doi: 10.1016/j.jvir.2007.04.018.
9
Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors With Massive Hepatic Tumor Burden: Is the Benefit Worth the Risk?
Ann Surg Oncol. 2016 Nov;23(12):4008-4015. doi: 10.1245/s10434-016-5333-x. Epub 2016 Jul 8.
10
Clinical features and outcomes of primary hepatic neuroendocrine carcinomas.原发性肝神经内分泌癌的临床特征和预后。
J Gastroenterol Hepatol. 2012 Aug;27(8):1306-11. doi: 10.1111/j.1440-1746.2012.07117.x.

引用本文的文献

1
Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.神经内分泌肝脏转移的肝脏导向局部治疗:最新进展与管理。
Curr Oncol. 2024 Apr 5;31(4):2076-2091. doi: 10.3390/curroncol31040154.
2
Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?肝细胞癌之外的化疗栓塞:我们可以治疗哪些肿瘤以及何时治疗?
Semin Intervent Radiol. 2024 Mar 14;41(1):27-47. doi: 10.1055/s-0043-1777716. eCollection 2024 Feb.
3
Integrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective Study.
卡培他滨-替莫唑胺联合放射性栓塞治疗肝优势型 G2 NETs:单中心回顾性研究的长期结果。
Cardiovasc Intervent Radiol. 2024 Jan;47(1):60-68. doi: 10.1007/s00270-023-03614-8. Epub 2023 Dec 6.
4
A Comparison of the Outcomes of Transarterial Chemoembolization and Transarterial Radioembolization in the Management of Neuroendocrine Liver Metastases in Adults: A Systematic Review.成人神经内分泌肝转移瘤治疗中经动脉化疗栓塞与经动脉放射性栓塞疗效的比较:一项系统评价
Cureus. 2023 Jun 18;15(6):e40592. doi: 10.7759/cureus.40592. eCollection 2023 Jun.
5
Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden.奥曲肽 LAR 联合经动脉栓塞治疗高肝肿瘤负荷的中低级别神经内分泌肿瘤肝转移患者获得长期无进展生存。
Cancer Med. 2022 Jul;11(13):2588-2600. doi: 10.1002/cam4.4628. Epub 2022 Mar 14.
6
The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review.介入放射学在神经内分泌肿瘤肝转移治疗中的作用:最新综述
J Clin Med. 2020 Jul 20;9(7):2302. doi: 10.3390/jcm9072302.
7
Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms.手术为非激素症状的转移性神经内分泌肿瘤患者提供长期生存。
J Gastrointest Surg. 2019 Jan;23(1):122-134. doi: 10.1007/s11605-018-3986-4. Epub 2018 Oct 17.
8
Liver transarterial embolizations in metastatic neuroendocrine tumors.转移性神经内分泌肿瘤的肝动脉栓塞术。
Rev Endocr Metab Disord. 2017 Dec;18(4):459-471. doi: 10.1007/s11154-017-9431-2.
9
Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results.阿霉素洗脱型超吸收性聚合物微球治疗神经内分泌肿瘤肝转移的安全性和有效性:初步结果
Radiol Oncol. 2017 Feb 22;51(1):74-80. doi: 10.1515/raon-2017-0007. eCollection 2017 Mar 1.
10
Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases.进展性神经内分泌肝转移患者的选择性内放射治疗
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1425-31. doi: 10.1007/s00259-015-3264-6. Epub 2015 Dec 3.